Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB).

Mayer IA, Prat A, Egle D, Blau S, Fidalgo JAP, Gnant M, Fasching PA, Colleoni M, Wolff AC, Winer EP, Singer CF, Hurvitz S, Estévez LG, van Dam PA, Kümmel S, Mundhenke C, Holmes F, Babbar N, Charbonnier L, Diaz-Padilla I, Vogl FD, Sellami D, Arteaga CL.

Clin Cancer Res. 2019 May 15;25(10):2975-2987. doi: 10.1158/1078-0432.CCR-18-3160. Epub 2019 Feb 5.

PMID:
30723140
2.

Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.

Campone M, Im SA, Iwata H, Clemons M, Ito Y, Awada A, Chia S, Jagiełło-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Cortés J, De Laurentiis M, Arteaga CL, Jiang Z, Jonat W, Le Mouhaër S, Sankaran B, Bourdeau L, El-Hashimy M, Sellami D, Baselga J.

Eur J Cancer. 2018 Nov;103:147-154. doi: 10.1016/j.ejca.2018.08.002. Epub 2018 Sep 18.

PMID:
30241001
3.

A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors.

Rodon J, Curigliano G, Delord JP, Harb W, Azaro A, Han Y, Wilke C, Donnet V, Sellami D, Beck T.

Oncotarget. 2018 Aug 3;9(60):31709-31718. doi: 10.18632/oncotarget.25854. eCollection 2018 Aug 3.

4.

Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1.

Soulières D, Licitra L, Mesía R, Remenár É, Li SH, Karpenko A, Chol M, Wang YA, Solovieff N, Bourdeau L, Sellami D, Faivre S.

Clin Cancer Res. 2018 Jun 1;24(11):2505-2516. doi: 10.1158/1078-0432.CCR-17-2644. Epub 2018 Feb 28.

5.

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.

Di Leo A, Johnston S, Lee KS, Ciruelos E, Lønning PE, Janni W, O'Regan R, Mouret-Reynier MA, Kalev D, Egle D, Csőszi T, Bordonaro R, Decker T, Tjan-Heijnen VCG, Blau S, Schirone A, Weber D, El-Hashimy M, Dharan B, Sellami D, Bachelot T.

Lancet Oncol. 2018 Jan;19(1):87-100. doi: 10.1016/S1470-2045(17)30688-5. Epub 2017 Dec 7. Erratum in: Lancet Oncol. 2018 Mar;19(3):e137.

PMID:
29223745
6.

Circulating tumor DNA as a novel tool to shape clinical trial designs with the potential to impact outcomes: a focus on PI3K inhibitors.

Sellami D, Dharan B, Wilke C, Scherer SJ, Hirawat S.

Ann Oncol. 2017 Nov 1;28(11):2882-2887. doi: 10.1093/annonc/mdx480. Review. No abstract available.

PMID:
28950291
7.

Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study.

Lear JT, Migden MR, Lewis KD, Chang ALS, Guminski A, Gutzmer R, Dirix L, Combemale P, Stratigos A, Plummer R, Castro H, Yi T, Mone M, Zhou J, Trefzer U, Kaatz M, Loquai C, Kudchadkar R, Sellami D, Dummer R.

J Eur Acad Dermatol Venereol. 2018 Mar;32(3):372-381. doi: 10.1111/jdv.14542. Epub 2017 Nov 6.

8.

Swept-Source Optical Coherence Tomography Angiography in West Nile Virus Chorioretinitis and Associated Occlusive Retinal Vasculitis.

Khairallah M, Kahloun R, Gargouri S, Jelliti B, Sellami D, Ben Yahia S, Feki J.

Ophthalmic Surg Lasers Imaging Retina. 2017 Aug 1;48(8):672-675. doi: 10.3928/23258160-20170802-11.

PMID:
28810044
9.

A Matching-Adjusted Indirect Comparison of Sonidegib and Vismodegib in Advanced Basal Cell Carcinoma.

Odom D, Mladsi D, Purser M, Kaye JA, Palaka E, Charter A, Jensen JA, Sellami D.

J Skin Cancer. 2017;2017:6121760. doi: 10.1155/2017/6121760. Epub 2017 May 21.

10.

Effects of Mild to Severe Hepatic Impairment on the Pharmacokinetics of Sonidegib: A Multicenter, Open-Label, Parallel-Group Study.

Horsmans Y, Zhou J, Liudmila M, Golor G, Shibolet O, Quinlan M, Emotte C, Boss H, Castro H, Sellami D, Preston RA.

Clin Pharmacokinet. 2018 Mar;57(3):345-354. doi: 10.1007/s40262-017-0560-2.

PMID:
28577129
11.

Early treatment with Nd-YAG laser for a premacular hemorrhage secondary to a retinal macroaneurysm.

Abid F, Sellami D, Ben Yahia S, Gargouri S, Ammous D, Khairallah M, Feki J.

J Fr Ophtalmol. 2017 Jan;40(1):e11-e13. doi: 10.1016/j.jfo.2016.07.016. Epub 2016 Nov 14. No abstract available.

13.

Effect of esomeprazole, a proton pump inhibitor on the pharmacokinetics of sonidegib in healthy volunteers.

Zhou J, Quinlan M, Glenn K, Boss H, Picard F, Castro H, Sellami D.

Br J Clin Pharmacol. 2016 Oct;82(4):1022-9. doi: 10.1111/bcp.13038. Epub 2016 Jul 13.

14.
15.

The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.

Dummer R, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, Herd RM, Kaatz M, Loquai C, Stratigos AJ, Schulze HJ, Plummer R, Gogov S, Pallaud C, Yi T, Mone M, Chang AL, Cornélis F, Kudchadkar R, Trefzer U, Lear JT, Sellami D, Migden MR.

J Am Acad Dermatol. 2016 Jul;75(1):113-125.e5. doi: 10.1016/j.jaad.2016.02.1226. Epub 2016 Apr 7.

16.

Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors.

Goel V, Hurh E, Stein A, Nedelman J, Zhou J, Chiparus O, Huang PH, Gogov S, Sellami D.

Cancer Chemother Pharmacol. 2016 Apr;77(4):745-55. doi: 10.1007/s00280-016-2982-1. Epub 2016 Feb 22.

PMID:
26898300
17.

Molecular Analysis of Libyan Families with Allgrove Syndrome: Geographic Expansion of the Ancestral Mutation c.1331+1G>A in North Africa.

Kallabi F, Ben Rebeh I, Felhi R, Sellami D, Masmoudi S, Keskes L, Kamoun H.

Horm Res Paediatr. 2016;85(1):18-21. doi: 10.1159/000441653. Epub 2015 Nov 24.

PMID:
26595337
18.

Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial.

Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, Herd RM, Kudchadkar R, Trefzer U, Gogov S, Pallaud C, Yi T, Mone M, Kaatz M, Loquai C, Stratigos AJ, Schulze HJ, Plummer R, Chang AL, Cornélis F, Lear JT, Sellami D, Dummer R.

Lancet Oncol. 2015 Jun;16(6):716-28. doi: 10.1016/S1470-2045(15)70100-2. Epub 2015 May 14.

PMID:
25981810
19.

Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus.

Huynh H, Hao HX, Chan SL, Chen D, Ong R, Soo KC, Pochanard P, Yang D, Ruddy D, Liu M, Derti A, Balak MN, Palmer MR, Wang Y, Lee BH, Sellami D, Zhu AX, Schlegel R, Huang A.

Mol Cancer Ther. 2015 May;14(5):1224-35. doi: 10.1158/1535-7163.MCT-14-0768. Epub 2015 Feb 27.

20.

The spectrum of presumed tubercular uveitis in Tunisia, North Africa.

Khochtali S, Gargouri S, Abroug N, Ksiaa I, Attia S, Sellami D, Feki J, Khairallah M.

Int Ophthalmol. 2015 Oct;35(5):663-71. doi: 10.1007/s10792-014-9992-y. Epub 2014 Sep 6.

PMID:
25192914
21.

Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.

Zhu AX, Kudo M, Assenat E, Cattan S, Kang YK, Lim HY, Poon RT, Blanc JF, Vogel A, Chen CL, Dorval E, Peck-Radosavljevic M, Santoro A, Daniele B, Furuse J, Jappe A, Perraud K, Anak O, Sellami DB, Chen LT.

JAMA. 2014 Jul 2;312(1):57-67. doi: 10.1001/jama.2014.7189.

PMID:
25058218
22.

Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma.

Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff T, Harker WG, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW, Page R, Bavbek S, Beck JT, Patel P, Cheung FY, Yadav S, Schiff EM, Wang X, Niolat J, Sellami D, Anak O, Knox JJ.

J Clin Oncol. 2014 Sep 1;32(25):2765-72. doi: 10.1200/JCO.2013.54.6911. Epub 2014 Jul 21.

23.

Relationship between everolimus exposure and safety and efficacy: meta-analysis of clinical trials in oncology.

Ravaud A, Urva SR, Grosch K, Cheung WK, Anak O, Sellami DB.

Eur J Cancer. 2014 Feb;50(3):486-95. doi: 10.1016/j.ejca.2013.11.022. Epub 2013 Dec 9.

PMID:
24332451
24.

Visual loss associated with rickettsial disease.

Kahloun R, Gargouri S, Abroug N, Sellami D, Ben Yahia S, Feki J, Khairallah M.

Ocul Immunol Inflamm. 2014 Oct;22(5):373-8. doi: 10.3109/09273948.2013.848907. Epub 2013 Oct 30.

PMID:
24171650
25.

Risk of thyroid cancer based on thyroid ultrasound imaging characteristics: results of a population-based study.

Smith-Bindman R, Lebda P, Feldstein VA, Sellami D, Goldstein RB, Brasic N, Jin C, Kornak J.

JAMA Intern Med. 2013 Oct 28;173(19):1788-96. doi: 10.1001/jamainternmed.2013.9245.

26.

Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.

Finn RS, Poon RT, Yau T, Klümpen HJ, Chen LT, Kang YK, Kim TY, Gomez-Martin C, Rodriguez-Lope C, Kunz T, Paquet T, Brandt U, Sellami D, Bruix J.

J Hepatol. 2013 Dec;59(6):1271-7. doi: 10.1016/j.jhep.2013.07.029. Epub 2013 Aug 6.

PMID:
23928403
27.

Effects of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study.

Peveling-Oberhag J, Zeuzem S, Yong WP, Kunz T, Paquet T, Bouillaud E, Urva S, Anak O, Sellami D, Kobalava Z.

Clin Ther. 2013 Mar;35(3):215-25. doi: 10.1016/j.clinthera.2013.02.007. Epub 2013 Mar 1.

PMID:
23453404
28.

[Use of silicone oil in vitreal hemorrhage complicating proliferated diabetic retinopathy].

Kharrat W, Turki K, Ben Amor H, Sellami D, Sellami A, Trigui A, Kamoun B, Ben Zina Z, Feki J.

J Fr Ophtalmol. 2009 Feb;32(2):98-103. doi: 10.1016/j.jfo.2009.01.002. Epub 2009 Mar 4. Review. French.

29.

[Ocular findings in Alport syndrome: 32 case studies].

Hentati N, Sellami D, Makni K, Kharrat M, Hachicha J, Hammadi A, Feki J.

J Fr Ophtalmol. 2008 Jun;31(6 Pt 1):597-604. French.

30.

[Retinal neovascularization with myelinated nerve fibers].

Sellami D, Bouacida W, Maalej A, Ben Amor S, Châabouni M, Kamoun B, Feki J.

J Fr Ophtalmol. 2008 Jan;31(1):e2. French.

31.

Epidemiology and risk factors for corneal graft rejection.

Sellami D, Abid S, Bouaouaja G, Ben Amor S, Kammoun B, Masmoudi M, Dabbeche K, Boumoud H, Ben Zina Z, Feki J.

Transplant Proc. 2007 Oct;39(8):2609-11.

PMID:
17954190
32.

[Discoid lupus erythematosus with eyelid involvement. A series of nine patients].

Mseddi M, Marrekchi S, Meziou TJ, Sellami D, Kammoun B, Feki J, Zahaf A, Turki H.

J Fr Ophtalmol. 2007 Mar;30(3):247-9. French.

33.

[Ophtalmologic manifestations of the xeroderma pigmentosum].

Mseddi M, Sellami D, Elloumi Y, Aloulou Y, Kammoun B, Turki H, Feki J, Zahaf A.

Tunis Med. 2006 Sep;84(9):542-4. French.

PMID:
17263199
34.

[Ocular manifestations associated with nephronophthisis and genetic study in three Tunisian families].

Sellami D, Makni K, Chaker H, Kharrat M, Hentati N, Kammoun K, Chabouni F, Ben Hamida M, Hachicha J, Salomon R, Antignac C, Ayadi H, Feki J.

J Fr Ophtalmol. 2006 Nov;29(9):1019-23. French.

35.

[Palpebral and ocular manifestations of atopic dermatitis].

Sellami D, Masmoudi A, Hentati N, Mseddi M, Turki H, Zahaf A, Feki J.

Ann Dermatol Venereol. 2006 Jun-Jul;133(6-7):590-2. French. No abstract available.

PMID:
16885853
36.

[Allgrove syndrome. Report on a family].

Sellami D, Bouacida W, Frikha F, Triki C, BenZina Z, Ben Salah S, Feki J, Sellami A.

J Fr Ophtalmol. 2006 Apr;29(4):418-21. French.

37.

[Ophthalmic manifestations of lipoid proteinosis].

Sellami D, Masmoudi A, Turki H, Mseddi M, Kammoun B, Elleuch N, Chaabouni F, Ben Zina Z, Feki J, Zahaf A.

Presse Med. 2006 May;35(5 Pt 1):796-8. French.

PMID:
16710149
38.

[Two cases of subretinal neovascular membrane in Vogt-Koyanagi-Harada syndrome].

Ketata A, Ben Zina Z, Hajji D, Sellami D, Abdelkefi A, Kharrat W, Bouaouaja G, Dabbeche K, Feki J.

J Fr Ophtalmol. 2006 Mar;29(3):302-6. French.

39.

[Total body irradiation: techniques and main indications].

Kochbati L, Besbes M, Frikha H, Sellami D, Gargouri W, Ben Ammar CN, Ben Aissia R, Benna F, Damak H, Maalej M.

Tunis Med. 2005 Oct;83(10):581-5. Review. French.

PMID:
16370205
40.

[Phthiriasis pubis palpebrarum in children. Diagnosis and treatment].

Charfi F, Ben Zina Z, Maazoun M, Kharrat W, Sellami D, Makni F, Ayadi A, Feki J.

J Fr Ophtalmol. 2005 Sep;28(7):765-8. French.

41.

[Peribulbar anaesthesia for strabismus surgery].

Kamoun B, Khlif H, Sellami D, Ghorbel I, Aloulou Y, Trigui A, Benzina Z, Feki J.

Tunis Med. 2005 Mar;83(3):143-5. French.

PMID:
15929441
42.

[Child orbital lymphoma: about one case].

Benzina Z, Khlif H, Sellami D, Sayadi I, Abdelmoula S, Trigui A, Kammoun B, Daoud J, Féki J.

Tunis Med. 2004 Sep;82(9):884-8. French.

PMID:
15693484
43.

[Palpebral seborrheic keratosis: a case study].

Kharrat W, Benzina Z, Khlif H, Sellami D, Ayadi L, Boudawarra T, Feki J.

J Fr Ophtalmol. 2004 Dec;27(10):1146-9. French.

44.

Radio-induced malignancies of the scalp about 98 patients with 150 lesions and literature review.

Maalej M, Frikha H, Kochbati L, Bouaouina N, Sellami D, Benna F, Gargouri W, Dhraief S, Nasr C, Daoud J, Hajji M, Fazaa B, Souissi R, Mokhtar I, Kamoun MR.

Cancer Radiother. 2004 Apr;8(2):81-7.

PMID:
15063875
45.

[Mammography screening of breast cancer in Tunisia. Results of first experience].

Kribi L, Sellami D, el Amri A, Mnif N, Ellouze T, Chebbi A, Ben Romdhane K, Hamza R.

Tunis Med. 2003 Jan;81(1):26-33. French.

PMID:
12708189
46.

Spontaneously detached extraocular rectus muscles following scleral buckling with soft silicone sponges. A report of two cases.

Marrakchi S, Malek I, Allagui I, Sellami D, Nacef L, Daghfous F, Ayed S.

Binocul Vis Strabismus Q. 2002;17(3):223-6. No abstract available.

PMID:
12171595
47.

[Purtscher-like retinopathy in systemic lupus erythematosus. Two cases].

Sellami D, Ben Zina Z, Jelliti B, Abid D, Feki J, Chaâbouni M.

J Fr Ophtalmol. 2002 Jan;25(1):52-5. French.

48.

Acute rejection following lung transplantation: limitations in accuracy of thin-section CT for diagnosis.

Gotway MB, Dawn SK, Sellami D, Golden JA, Reddy GP, Keith FM, Webb WR.

Radiology. 2001 Oct;221(1):207-12.

PMID:
11568342
49.

Minute pulmonary meningothelial-like nodules: thin-section CT appearance.

Sellami D, Gotway MB, Hanks DK, Webb WR.

J Comput Assist Tomogr. 2001 Mar-Apr;25(2):311-3.

PMID:
11242234
50.

Hypersensitivity pneumonitis: patterns on high-resolution CT.

Patel RA, Sellami D, Gotway MB, Golden JA, Webb WR.

J Comput Assist Tomogr. 2000 Nov-Dec;24(6):965-70.

PMID:
11105719

Supplemental Content

Loading ...
Support Center